ArticleOncotarget2017

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.

Qiang Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.